Literature DB >> 24231522

Fish-oil emulsion (omega-3 polyunsaturated fatty acids) attenuates acute lung injury induced by intestinal ischemia-reperfusion through Adenosine 5'-monophosphate-activated protein kinase-sirtuin1 pathway.

Huirong Jing1, Jihong Yao2, Xingming Liu1, Hui Fan1, Feng Zhang1, Zhenlu Li1, Xiaofeng Tian3, Yun Zhou4.   

Abstract

BACKGROUND: Activated macrophage infiltration into the lungs is paramount in the pathogenesis of acute lung injury (ALI) induced by intestinal ischemia-reperfusion (I/R). Omega-3 polyunsaturated fatty acid (ω-3 PUFA) is a potent activator of the Adenosine 5'-monophosphate-activated protein kinase-sirtuin1 (AMPK/SIRT1) pathway against macrophage inflammation. We aimed to evaluate whether ω-3 PUFAs may protect against ALI induced by intestinal I/R via the AMPK/SIRT1 pathway.
METHODS: Ischemia in male Wistar rats was induced by superior mesenteric artery occlusion for 60 min and reperfusion for 240 min. One milliliter per day of fish-oil emulsion (FO emulsion, containing major ingredients as ω-3 PUFAs) or normal saline (control) was administered by intraperitoneal injection for three consecutive days to each animal. All animals were sacrificed at the end of reperfusion. Blood and tissue samples were collected for analysis.
RESULTS: Intestinal I/R caused intestinal and lung injury, evidenced by severe lung tissue edema and macrophage infiltration. Pretreatment with FO emulsion improved the integrity of microscopic structures in the intestine and lungs. Intestinal I/R induced the expression of macrophage-derived mediators (macrophage migration inhibitory factor and macrophage chemoattractant protein-1), inflammatory factors (nuclear factor κB, tumor necrosis factor α, interleukin 6, and interleukin 1β), and proapoptosis factor p66shc. There was a decrease in the expression of AMPK, SIRT1, and claudin 5. FO emulsion significantly inhibited macrophage infiltration into the lungs, inflammatory factor expression, and p66shc phosphorylation. Importantly, FO emulsion restored AMPK, SIRT1, and claudin 5 in the lungs.
CONCLUSIONS: Pretreatment with ω-3 PUFAs effectively protects intestinal and lung injury induced by intestinal I/R, reduces macrophage infiltration, suppresses inflammation, inhibits lung apoptosis, and improves the lung endothelial barrier after intestinal I/R in a manner dependent on AMPK/SIRT1. Thus, there is a potential for developing AMPK/SIRT1 as a novel target for patients with intestinal I/R-induced ALI.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AMPK/SIRT1; Fish oil; Intestinal ischemia–reperfusion; Lung injury; Macrophage; ω-3 PUFAs

Mesh:

Substances:

Year:  2013        PMID: 24231522     DOI: 10.1016/j.jss.2013.10.009

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  21 in total

1.  Pre-treatment with metformin activates Nrf2 antioxidant pathways and inhibits inflammatory responses through induction of AMPK after transient global cerebral ischemia.

Authors:  Ghorbangol Ashabi; Leila Khalaj; Fariba Khodagholi; Mahdi Goudarzvand; Alireza Sarkaki
Journal:  Metab Brain Dis       Date:  2014-11-21       Impact factor: 3.584

2.  Propofol Protects Rats and Human Alveolar Epithelial Cells Against Lipopolysaccharide-Induced Acute Lung Injury via Inhibiting HMGB1 Expression.

Authors:  Xiaoyan Wang; Chengxiao Liu; Gongming Wang
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  Polyunsaturated fatty acid induces cardioprotection against ischemia-reperfusion through the inhibition of NF-kappaB and induction of Nrf2.

Authors:  Jorge G Farías; Catalina Carrasco-Pozo; Rodrigo Carrasco Loza; Néstor Sepúlveda; Pedro Álvarez; Mauricio Quezada; John Quiñones; Víctor Molina; Rodrigo L Castillo
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

Review 4.  Sirt1: Role Under the Condition of Ischemia/Hypoxia.

Authors:  Xiaofei Meng; Jin Tan; Mengmeng Li; Shuling Song; Yuyang Miao; Qiang Zhang
Journal:  Cell Mol Neurobiol       Date:  2016-03-14       Impact factor: 5.046

Review 5.  New aspects of p66Shc in ischaemia reperfusion injury and other cardiovascular diseases.

Authors:  Fabio Di Lisa; Marco Giorgio; Peter Ferdinandy; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2016-04-14       Impact factor: 8.739

6.  Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model.

Authors:  Inderjit Singh; Devadoss J Samuvel; Seungho Choi; Nishant Saxena; Avtar K Singh; Jeseong Won
Journal:  Immunology       Date:  2018-02-08       Impact factor: 7.397

7.  Protective effects of polyunsatutared fatty acids supplementation against testicular damage induced by intermittent hypobaric hypoxia in rats.

Authors:  Rodrigo L Castillo; Andrea B Zepeda; Stefania E Short; Elías Figueroa; Eduardo Bustos-Obregon; Jorge G Farías
Journal:  J Biomed Sci       Date:  2015-01-23       Impact factor: 8.410

Review 8.  Cellular Signal Transduction Pathways Involved in Acute Lung Injury Induced by Intestinal Ischemia-Reperfusion.

Authors:  Guangyao Li; Yingyi Zhang; Zhe Fan
Journal:  Oxid Med Cell Longev       Date:  2021-06-04       Impact factor: 6.543

9.  A Peptide to Reduce Pulmonary Edema in a Rat Model of Lung Transplantation.

Authors:  Klaudia Schossleitner; Andreas Habertheuer; Richard Finsterwalder; Heinz P Friedl; Sabine Rauscher; Marion Gröger; Alfred Kocher; Christine Wagner; Stephan N Wagner; Gottfried Fischer; Marcus J Schultz; Dominik Wiedemann; Peter Petzelbauer
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

10.  High Endogenous Accumulation of ω-3 Polyunsaturated Fatty Acids Protect against Ischemia-Reperfusion Renal Injury through AMPK-Mediated Autophagy in Fat-1 Mice.

Authors:  Do Hyeong Gwon; Tae Woong Hwang; Ju-Ye Ro; Yoon-Joong Kang; Jin Young Jeong; Do-Kyung Kim; Kyu Lim; Dong Woon Kim; Dae Eun Choi; Jwa-Jin Kim
Journal:  Int J Mol Sci       Date:  2017-09-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.